NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON Russian patent published in 2012 - IPC C07K14/56 A61K38/21 A61K47/48 A61P37/00 A61P35/00 A61P31/12 

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to obtaining PEGylated interferon alpha (IFN-alpha), and can be used in medicine. A conjugate of IFN-alpha with monomethoxypolyethylene glycol, bonded to N-terminal IFN-cysteine alpha of general formula , is obtained, where: n is a whole number from 454 to 1000; m is a whole number ≥4; NαH-IFN is interferon-α-2b, having interferon alpha activity.

EFFECT: obtained conjugate has IFN-alpha activity and prolonged biological action, which enables its use in pharmaceutical compositions and as a medicinal agent for preventing or treating viral and oncological diseases and diseases accompanied by primary or secondary immunodeficiency states.

23 cl, 9 dwg, 6 tbl, 20 ex